Gufic Biosciences (509079) Q3 25/26 earnings summary

Executive summary

• Domestic branded portfolio emphasizes protocol-led depth, science-backed differentiation, and scaling, with a focus on hospital injectables, critical care, women's health, fertility, and botulinum toxin platforms; international expansion supported by Indore facility and robust R&D.

• Achieved commercial production at Indore injectable facility, targeting global regulated markets and reaching 30% utilization in Q3 FY25.

• Strong partnerships and licensing deals with global pharma and biotech leaders, enhancing technology and product pipeline.

• Standalone and consolidated unaudited financial results for the quarter and nine months ended December 31, 2025, were reviewed and approved by the Board on February 13, 2026.

• Statutory auditors conducted a limited review and found no material misstatements or non-disclosures in the financial statements.

Financial highlights

• Q3 FY26 revenue was ₹231.1 Cr, up from ₹207.8 Cr in Q3 FY25; 9M FY26 revenue at ₹688.4 Cr, up from ₹614.8 Cr YoY.

• Q3 FY26 EBITDA was ₹37.1 Cr (16.05% margin), slightly down from 17.23% in Q3 FY25; 9M FY26 EBITDA at ₹108.2 Cr.

• Q3 FY26 PAT was ₹15.6 Cr (6.75% margin), down from ₹19.3 Cr (9.29%) in Q3 FY25; 9M FY26 PAT at ₹42.6 Cr.

• Standalone revenue for the quarter was ₹23,109.36 lakhs, with consolidated revenue at ₹23,220.04 lakhs; standalone net profit was ₹1,556.39 lakhs, consolidated net profit was ₹1,682.40 lakhs.

• Basic and diluted EPS for the quarter were ₹1.55 (standalone) and ₹1.68 (consolidated).

Outlook and guidance

• FY27 revenue growth guidance set at a minimum of 15%, with potential upside to 20% depending on regulatory and export ramp-up.

• Indore facility expected to be margin accretive by FY27, with global regulatory clearances and US FDA readiness by FY29.

• Strategic roadmap targets 5-10% market share in identified geographies over 3-5 years, leveraging expanded manufacturing and product portfolio.

• Export revenue from Indore to regulated markets expected to start in Q3/Q4 FY27.